CSF1R and neoplasm: Each of the myeloid cell inhibitors, including anti-Ly6G, anti-GR1, anti-Ly6C, anti-CSF1R antibodies, and CL decreased their respective mouse TIM subsets, enhancing T-BsAb-driven T cell infiltration and persistence, resulting in improved anti-tumor response.